Tetra Bio-Pharma Accelerates its European Drug Registration Activities
Momentum Public Relations
Press Release: September 11, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.
This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs. According to Dr. Guy Chamberland, Interim CEO and CSO, “the corporation has performed its own clinical trials and has sufficient quality and clinical trial data to initiate the application for the registration of PPP001 and PPP005 under the Directive 2001/83/EC. Tetra intends to pursue a Full Market Authorisation since it has a dossier supporting the medicinal product’s quality, safety, and efficacy.”
All of Tetra’s clinical trials were performed with the same quality of evidence required by the National Competent authorities approving medicines/drugs. Tetra has completed several well-designed safety, pharmacodynamic and pharmacokinetic studies in healthy volunteers and also has two ongoing, well-designed clinical trials in patients. These trials are all double-blind, randomized and placebo controlled.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Secures CBD Supply Agreement for Genacol Partnership
Momentum Public Relations
Press Release: September 5, 2018
Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation which will be commercialized under the previously announced partnership with Genacol.
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create these innovative products for Genacol. Tetra Bio-Pharma will work with the appropriate regulatory agencies to gain marketing authority within Genacol’s international sales network where their brand products are available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. According to industry statistics the market for topical pain relief products exceeds $2.5 billion. The products are expected to be launched in 2019.
“We are very pleased to secure a competitive supply agreement with True North Cannabis as Tetra is committed on bringing innovative cannabinoid products to market,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “True North Cannabis has built a state-of-the-art facility in Alberta which will provide the highest quality CBD for Tetra, at a competitive price, to develop innovative products in partnership with Genacol. Price to consumers is a critical aspect for the viability of a commercial product in the self-care health market. At Tetra Bio-Pharma we are focused on becoming a global leader in the development of cannabinoid derived prescription and natural health products.”
“True North Cannabis is pleased to enter into a commercial relationship to supply hemp-based CBD to Tetra Bio-Pharma,” Shayne Hamilton, Chief Executive Officer of True North Cannabis commented. “Our business leverages the size and scale of the industrial hemp crop in Canada to provide a competitively priced, reliable source of CBD. Tetra Bio-Pharma’s vast experience in pharmaceutical product development, along with Genacol’s robust distribution footprint, presents True North Cannabis a unique opportunity to market our product.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About True North Cannabis
True North Cannabis (TNC) is a Canadian hemp harvest service provider with a core focus on facilitating the supply of bulk, extract-ready, hemp-based CBD.
With a grower-focused service model, TNC supports industrial hemp growers across Canada to effectively commercialize the cannabinoid content from their harvest. By providing access to state of the art infrastructure and hemp chaff expertise, TNC manages the unique challenges in bridging broad acre agriculture and the Cannabis industry.
For more information visit: www.truenorthcannabis.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease
Momentum Public Relations
Press Release: September 5, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an agreement to provide a telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics (“Optina”) for a period of 3 years. Optina will use DIAGNOS Cloud services to upload images generated by Optina’s hyperspectral camera for early detection of Alzheimer via key biomarkers in the retina of the eye.
The processed images will be available to be shared and further analysed by healthcare professionals and clinics in various locations. Optina will benefit from the high throughput of DIAGNOS CARA Cloud service as well as the ease of use of the teleophthalmology platform currently used by doctors and other medical professionals.
“At DIAGNOS, we are extremely happy to contribute to the success of innovative Quebec companies like Optina. Optina will leverage our experience and the high quality standard of CARA, a field proven platform approved for sale by the Food and Drug Administration in the United States, Health Canada and other countries’ homologation bodies. This partnership will foster more collaboration with other biotech firms and attract new clients in need of a telemedicine platform.” said Yves-Stephane Couture, Vice-President of sales at DIAGNOS.
“The partnership will greatly accelerate Optina’s commercialization of its Alzheimer diagnostic test, saving critical time to market while providing effective and efficient user experience.” said David Lapointe, President and CEO of Optina.
About Optina
Optina Diagnostics is a Montreal based company focused on the development of technology for the early detection of disease through hyperspectral imaging of the eye. With a first application in the early diagnosis of Alzheimer’s, Optina brings a radiomics approach to biomarker detection.
Additional information about Optina is available at www.optinadx.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
- Published in Business, Diagnos, Life Sciences, News Home, Technology
Tetra Bio-Pharma Announces Record Date for Dividend-in-Kind of North Bud Farms Shares
Momentum Public Relations
Press Release: August 31, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that its board of directors has declared a dividend-in-kind (the “Dividend”) of 15,500,000 common shares (each a “North Bud Share“) of North Bud Farms Inc. (“North Bud“) owned by Tetra pro rata to the holders of record of outstanding common shares (each, a “Tetra Share“) of Tetra (the “Shareholders of Record“) as at September 7, 2018 (the “Dividend Record Date”). The Dividend will be payable on September 12, 2018. Tetra Shares purchased on the TSX Venture Exchange (the “Exchange“) on or after September 6, 2018 will not be eligible to receive the Dividend. The Corporation would like to remind all holders of Tetra options or warrants who intend to exercise their securities and participate in the Dividend that they should proceed to do so well in advance of the ex-dividend date in order to ensure that they are eligible to receive the Dividend.
The North Bud Shares were acquired by the Corporation in connection with the previously announced sale by the Corporation of GrowPros MMP Inc., details of which are contained in the Corporation’s previous press releases issued on December 21, 2017 and February 22, 2018. The Corporation has filed a Form 3E with the TSX Venture Exchange in respect of the Dividend, notifying the TSX Venture Exchange of the Dividend Record Date.
The Dividend will be paid and satisfied in full by the Corporation transferring the North Bud Shares to the Shareholders of Record on the Record Date, on a pro ratabasis, subject to certain adjustments to account for the Corporation’s withholding obligations under applicable tax laws (as described below). No fractional North Bud Shares, cash or any other form of payment will be payable under the Dividend. Any fractional interests in North Bud Shares under the Dividend will be rounded down to the nearest whole number of shares. Based upon the number of Tetra Shares currently outstanding, and without taking into account the exercise of any options or warrants currently outstanding or the effect of rounding for fractional interests, approximately 0.1012 North Bud Shares will be paid under the Dividend for every 1 Tetra Share held by a Shareholder of Record on the Record Date.
The Dividend will be an “eligible dividend” for the purposes of the Income Tax Act (Canada) and corresponding provincial legislation. The Dividend will be taxable and non-residents of Canada will be subject to Canadian withholding taxes. In order to comply with its statutory withholding obligations, Tetra will, with respect to Shareholders of Record having a registered address outside of Canada on the Record Date, withhold and retain all interest, right and title to that number of North Bud Shares required to meet the Company’s withholding obligations with respect to such shareholders (the “Withheld Shares“) and remit to the Canada Revenue Agency, in cash, the equivalent of the fair market value of the Withheld Shares. The fair market value of the North Bud Shares distributed under the Dividend shall be, subject to certain exceptions, equal to the volume weighted average trading price of the common shares in the capital of North Bud on the Exchange for a period of 5 consecutive trading days prior to the Dividend payment date. Shareholders of Record with questions regarding the tax treatment of the Dividend in their personal circumstances should consult with their own tax advisors or contact their local office of the Canada Revenue Agency and, where applicable, the provincial taxation authorities.
North Bud has filed a final prospectus on August 21, 2018 with the Ontario Securities Commission. The prospectus is available on SEDAR under North Bud’s profile at www.sedar.com. Shareholders are urged to read the prospectus in full, as it contains important information regarding the Dividend, including regarding certain risk factors and certain income tax matters.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction. The North Bud Shares may not be offered or sold in the United States by holders thereof unless registered under the U.S. Securities Act of 1933, as amended, and applicable state securities laws or an exemption from such registration is available.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About North Bud Farms Inc.
North Bud Farms Inc., through its subsidiary GrowPros MMP Inc., is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud is dedicated to the production of both pharmaceutical and food grade cannabinoid inputs. North Bud recently became a reporting issuer in Ontario and has received conditional acceptance to list its common shares on the Canadian Securities Exchange (CSE) under the symbol NBUD.
- Published in Life Sciences, Marijuana, Medical Marijuana, Tetra Bio Pharma
Tetra Bio-Pharma Adds New Marketing Vice-President
Momentum Public Relations
Press Release: August 30, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018. He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities.
Steeve has more than 32 years’ experience in the pharmaceutical industry with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology where challenging the reimbursement landscape factored prominently in his role. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada, formerly Valeant.
Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).
“I am very proud to add Steeve to our senior management team. His vast experience will enable Tetra to achieve its high standards in executional excellence,” says Richard Giguere Executive Vice-President, Commercial Operations.
“I am very excited to have the opportunity of contributing my pharmaceutical marketing knowledge within the growing cannabinoid-based products sector,” said Steeve Neron. “Tetra has set the bar high from a clinical development standpoint and this is a critical factor to maximize the therapeutic potential of cannabis.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Sirona Biochem Receives $500,000 USD Milestone Payment from Wanbang Biopharmaceuticals
Momentum Public Relations
Press Release: August 28, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) announced that it has received the $500,000 USD milestone payment from partner Wanbang Biopharmaceuticals Co., Ltd (“Wanbang”) for approval by the China Food and Drug Administration of the Phase I Clinical Trial for Sirona’s SGLT-2 inhibitor. Sirona’s SGLT-2 inhibitor, TFC-039, will continue to be developed for the treatment of Type 2 diabetes. Since the two companies signed a licensing agreement in 2014, Sirona Biochem has secured $1.5 million USD in development milestones from Wanbang.
Shortly after the announcement of the approval, Sirona CEO, Dr. Howard Verrico met with the Wanbang team at the Shanghai Fosun Pharmaceutical Industrial Development Company Limited (“Fosun”) headquarters in Shanghai. The meeting focused on next steps in the development of “Wangeliejin”, the name for TFC-039. Wanbang expressed their full dedication to the SGLT-2 inhibitor project. The team also shared that while Wanbang has primarily focused on developing generic drugs, developing TFC-039 shows a need for such a medication in China and their belief in Sirona’s compound. They have heavily invested time and money into the first phase of testing and are dedicated to continuing through to market. Clinical trials are currently being set up and anticipated to begin as early as October – a milestone achievement for both teams.
“As we move into the second half of 2018, we are pleased with the dedication and progress Fosun has made in developing Sirona’s SGLT-2 inhibitor for the Chinese market. Following our most recent meeting in Shanghai, both teams remain enthused about the project and partnership,” said Dr. Howard Verrico, CEO. “Wanbang’s powerful marketing, distribution and retail channels allows them to maintain a strong position in the diabetes treatment market. We look forward to the continued progress in working towards a treatment for Type-2 diabetes.”
About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals
Wanbang Biopharmaceuticals develops, manufactures and sells drugs with indications for chronic disease treatment including endocrine diseases in China. Founded in 1981, they are presently headquartered in Xuzhou, China and are a subsidiary of Shanghai Fosun Pharmaceutical Co., Ltd. Fosun is a leader in the pharmaceutical industry and regarded as one of the top domestic pharmaceutical companies in China. For more information on Fosun and Wanbang, visit https://www.fosunpharma.com/en/.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Life Sciences, News Home, Sirona Biochem
DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants
Momentum Public Relations
Press Release: August 24, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 1,333,333 units (each a “Unit”) issued at $0.075 per Unit for gross proceeds of up to $100,000. Each Unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.10 per Share, for a period of 18 months from the date of issuance of the Warrant.
The proceeds will be used to fund marketing and administrative expenses.
Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.
Closing of the Private Placement is scheduled for August 30, 2018. The Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Business, Diagnos, Life Sciences, News Home, Technology
Tetra Bio-Pharma applies for orphan drug designation for CBDs
Momentum Public Relations
Press Release: August 23, 2018
Tetra Bio-Pharma Inc.(“Tetra” or “TBP”), today announced the submission of multiple applications for Orphan Drug Designation for cannabinoids to the U.S. Food and Drug Administration, for the treatment of various forms of rare cancers and ocular diseases. The applications align with Tetra’s strategy to develop cannabis prescription drug products for the treatment of several rare cancers and to expand its market exclusivity in the treatment of ocular diseases. If successful, the designation of cannabinoids as an Orphan Drug will open the door for fast track approval, tax credits on clinical research, and reduced registration fees, in addition to other opportunities. It further provides Tetra with a 7-year period of market exclusivity in the U.S.
Today’s announcement builds on previous milestones for Tetra in cancer, ocular disease and pain conditions. In May 2017, Tetra announced its partnership with Panag Pharma to develop innovative cannabinoid-based prescription drugs for the treatment of ocular inflammatory and pain conditions. The company also announced it submitted patent applications to expand its exclusivity for the development of pharmaceutical drug formulations to treat various forms of cancer and ocular disease. This latter protection complements the intellectual property owned by Panag Pharma.
In March 2018, Tetra announced that the U.S. FDA granted an Orphan Drug Designation for Complex Regional Pain Syndrome. The company has expanded its regulatory activities in the USA to accelerate making cannabinoid-based prescription drugs accessible to patients.
“Managing rare forms of cancer presents a huge challenge for physicians,” said Dr. Guy Chamberland, M.Sc., Ph.D., interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Our R&D team has submitted numerous Orphan Drug Designation applications to the FDA over the past 6 months, which not only holds promise to improve patient care but lines up with our corporate strategy to develop and commercialize cannabinoid prescription drug products for both rare cancers and ocular diseases in the United States.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Relevium to Host Webcast to Discuss Previously Announced Blockchain Project
Momentum Public Relations
Press Release: January 18th, 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTC PINK:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce that it will be hosting a webcast in conjunction with Quantomic LLC to discuss Tagspire, the virtual intelligent e-retail platform and artificial intelligence technology stack.
Management and the Board of Relevium have been monitoring public forums and have received multiple questions regarding the January 11, 2018 announcement of a Joint Venture (the “JV”) between the Company and Quantomic LLC. In order to provide clarity and answer these important questions, the Company will be hosting a Webcast, and invites all stakeholders to participate in this exciting information session.
Webcast Details
Relevium – in conjunction with Quantomic LLC – will be hosting a Q&A information webcast on Monday January 22, 2018 at 16:15 ET with Mr. Aurelio Useche, President and CEO of Relevium, and Mr. Karim Hijazi, Founder and CEO of Quantomic LLC.
Investors can email questions for Management to investors@releviumcorp.com prior to 11:59 a.m. ET on Monday January 22, 2018 and they will be addressed on the webcast at the discretion of Management.
During the webcast, the two CEOs will discuss the genesis of Tagspire, the strategic fit between the companies, and explain their shared vision for this exciting platform and technology. In addition, the Company will seek to answer questions that have been raised by shareholders and give guidance on the direction that the Company foresees for the JV, the proposed initial coin/token offering (the “ICO”) and impact for current Relevium shareholders.
Mr. Aurelio Useche, President and CEO of Relevium stated: “We are excited to join forces with Karim Hijazi, founder and CEO of Quantomic LLC and creator of Tagspire.” Mr. Useche continued: “Karim is an accomplished member and leader in the cyber-security community with a track record of previous exits in this space, making this information session a must attend for all our stakeholders.”
Date | Monday, January 22, 2018 | |
Time | 4:15 p.m. ET | |
Conference dial-ins: | ||
Canada | 1 (647) 497 9389 | 1 888 816 4438 |
United States | 1 (951) 384-3421 | 1 866 901 6455 |
Registration URL | https://attendee.gotowebinar.c |
|
Webinar ID | 673-021-811 |
A recording of the webcast will be available upon request. Please email requests to investors@releviumcorp.com for a link to the recording.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
Edward Ierfino
Investor Relations
+1(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in Financial Technology, Life Sciences, Nutraceutical, Relevium Technologies, Technology
Sharc International Systems Announces Newest PIRANHA™ System
Momentum Public Relations
Press Release: October 31, 2017
VANCOUVER, British Columbia, Oct. 31, 2017 (GLOBE NEWSWIRE) — Sharc International Systems Inc. (CSE:SHRC) (FSE:IWIA) (OTCQB:INTWD) (“SHARC” or “the Company”) is pleased to announce that the Company has completed the in-house design of the newest PIRANHA™ wastewater heat exchange system, (the “PIRANHA HC”).
The PIRANHA HC is a self-contained heat exchange system specifically designed to provide domestic hot water pre-heating and space conditioning (heating and cooling). With its specially engineered direct expansion heat exchanger, the PIRANHA HC is designed for multi-unit residential (50-200 units) and stand-alone commercial applications.
The PIRANHA HC is easily installed in new and retrofit construction projects, is attributable to LEED® credit criterion, and promotes the numerous environmental and energy-saving benefits of an expertly engineered wastewater heat exchange system.
While SHARC’s signature PIRANHA™ system provides domestic water pre-heating, the PIRANHA HC’s added space conditioning feature provides even greater carbon reduction and energy savings. Whether it’s for a building’s lobby, training facility, or conference room, the PIRANHA HC can provide strategic and specific space conditioning that eliminates the need for additional equipment. The PIRANHA HC’s compact system frees up space for developers and building owners to add further amenities or suites, while improving the building’s overall energy efficiency.
The PIRANHA HC’s multi-functionality provides a short payback for users as it operates at efficiencies of 400-600{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}. Water and space heating represent some of the highest operating costs for buildings and the PIRANHA HC works to significantly reduce these costs. With a robust design and lifecycle of 25+ years, the PIRANHA HC is dedicated to delivering clean energy for the long-term.
SHARC is also pleased to announce that it is a finalist for the 2018 AHR Expo® Innovation Award for Green Building Innovation.
The AHR Expo® is the world’s largest HVACR (Heating, Ventilating, Air Conditioning and Refrigeration) convention. The annual AHR Expo® Innovation Awards competition honors the most inventive and original products, systems and technologies showcased at each year’s AHR Expo. Products go head-to-head in the following categories: building automation; cooling; green building; heating; indoor air quality; plumbing; refrigeration; software; tools & instruments; and ventilation. Winners are selected by a panel of third-party ASHRAE member judges who evaluate all award entries based on innovative design, value, creativity, application, and market impact.
SHARC’s PIRANHA HC was chosen as a finalist among elite company in the HVACR market. The award is a result of the Company’s ambition to meet the growing demand for clean technology through delivering a highly-efficient compact device that provides multiple services.
SHARC will be attending the annual AHR Expo® in Chicago from January 22-24, 2018, at Booth 5097.
About Sharc International Systems
Sharc International Systems is a world leader in thermal heat recovery. Its systems recycle thermal energy from waste water, generating the most energy-efficient and economical systems for heating, cooling and hot water for commercial, residential and industrial buildings.
Further information about the Company is available on our website at www.sharcenergy.com or under our profile on SEDAR at www.sedar.com.
ON BEHALF OF THE BOARD
“Lynn Mueller”
Chairman and Chief Executive Officer
For further information, please contact:
Sharc International Systems Inc.
Zach Hillhouse
Phone: +1 (604) 475-7710
Email: zach.hillhouse@iws-sharc.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. SHARC’s actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. SHARC believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
- Published in International Wastewater Systems, Life Sciences, News Home, Technology